Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

• Ability to mobilize an adequate number of autologous PBSC [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  

• Toxicity assessed by NCI CTCAE v3.0 [ Time Frame: Up to 30 days post-treatment ] [ Designated as safety issue: Yes ]
  
• Engraftment after transplant as assessed by initial neutrophil recovery [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  
• Delayed platelet engraftment after transplant [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]
  
• Secondary graft failure [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  
• Tumor status [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  

OBJECTIVES:

I. Determine the number of days of apheresis required to reach >= 5 x 10^6 CD34 cells/kg.

II. Determine the number of CD34 cells/kg collected in a maximum of 4 days if >= 5 x 10^6 CD34 cells/kg is not obtained.

OUTLINE:

Patients receive rituximab IV on day 1, etoposide IV on days 2-4, and carboplatin and ifosfamide IV on day 3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.

After completion of study treatment, patients are followed periodically for up to 12 months.